Vtama cream combined with injectable biologics may improve psoriasis outcomes

Key takeaways:

• The study’s goal was for psoriasis patients to achieve 1% or less body surface area involvement after 3 months of treatment.
• 52% of patients treated with Vtama cream 1% as an add-on therapy achieved this goal.

Vtama cream 1% may be used in combination with an injectable biologic for the treatment of plaque psoriasis, according to a Schweiger Dermatology Group press release.

The Psoriasis Treatment Center of New Jersey announced positive results from its single-center, open-label, observational study evaluating Vtama cream 1% (tapinarof, Dermavant Sciences) as an add-on treatment to injectable biologics for patients with plaque psoriasis. The treatment center is part of the Schweiger Dermatology Group.

According to the press release, the study sought to fulfill the National Psoriasis Foundation’s treatment goal of patients with psoriasis achieving less than 1% affected body surface area after 3 months of treatment.

In the study, 30 patients with 3% or more body surface area involvement that had been on a biologic therapy for at least 26 weeks used Vtama once daily for 12 weeks as an add-on therapy.

Results showed that 52% of patients who followed this regimen achieved a body surface area involvement of 1% or less within 3 months of starting Vtama. These patients also achieved PASI 75 at week 12 and maintained clearance through week 16, 4 weeks after Vtama discontinuation.

Of the three patients with genital involvement, all achieved clearance by week 12.

According to the release, Vtama was well tolerated when used in combination with injectable biologics. No new safety signals or serious adverse events were reported, and there was only one mild case of folliculitis.

Further results from this study will be announced at an upcoming medical meeting, according to the press release.